* history of sars-cov-2 infection in the past 6 months * experiencing measured fever (documented temperature \>38˚c or 100.4˚f) or other signs or symptoms consistent with covid-19 * known medical history of active liver disease * chronic kidney disease or have known moderate to severe renal impairment. * known human immunodeficiency virus (hiv) infection with viral load \> 400 copies/ml within the last 6 months or taking prohibited medications for hiv treatment * suspected or confirmed concurrent active systemic infection * active cancer requiring treatment with prohibited medication. * current or expected use of any medications or substances that are highly dependent on cytochrome p450 3a4 (cyp3a4) for clearance or are strong inducers of cyp3a4 * has received approved, authorized, or investigational anti-sars-cov-2 mab, convalescent plasma, other drugs for treatment of covid-19, or other anti-sars-cov-2 biologic products within 6 months of screening * has received any sars-cov-2 vaccine within 6 months prior to screening or is expected to receive a sars-cov-2 vaccine or other approved, authorized, or investigational postexposure prophylaxis treatments through day 38. * participating in another interventional clinical study with an investigational compound or device, including those for covid-19 * known or prior participation in this trial or another trial involving pf-07321332. * females who are pregnant or breastfeeding.

* history of sars-cov-2 infection in the past 6 months * experiencing measured fever (documented temperature \>38˚c or 100.4˚f) or other signs or symptoms consistent with covid-19 * known medical history of active liver disease * chronic kidney disease or have known moderate to severe renal impairment. * known human immunodeficiency virus (hiv) infection with viral load \> 400 copies/ml within the last 6 months or taking prohibited medications for hiv treatment * suspected or confirmed concurrent active systemic infection * active cancer requiring treatment with prohibited medication. * current or expected use of any medications or substances that are highly dependent on cytochrome p450 3a4 (cyp3a4) for clearance or are strong inducers of cyp3a4 * has received approved, authorized, or investigational anti-sars-cov-2 mab, convalescent plasma, other drugs for treatment of covid-19, or other anti-sars-cov-2 biologic products within 6 months of screening * has received any sars-cov-2 vaccine within 6 months prior to screening or is expected to receive a sars-cov-2 vaccine or other approved, authorized, or investigational postexposure prophylaxis treatments through day 38. * participating in another interventional clinical study with an investigational compound or device, including those for covid-19 * known or prior participation in this trial or another trial involving pf-07321332. * females who are pregnant or breastfeeding.

history of sars-cov-2 infection in the past 6 months experiencing measured fever (documented temperature >38˚c or 100.4˚f) or other signs or symptoms consistent with covid-19 known medical history of active liver disease chronic kidney disease or have known moderate to severe renal impairment. known human immunodeficiency virus (hiv) infection with viral load > 400 copies/ml within the last 6 months or taking prohibited medications for hiv treatment suspected or confirmed concurrent active systemic infection active cancer requiring treatment with prohibited medication. current or expected use of any medications or substances that are highly dependent on cytochrome p450 3a4 (cyp3a4) for clearance or are strong inducers of cyp3a4 has received approved, authorized, or investigational anti-sars-cov-2 mab, convalescent plasma, other drugs for treatment of covid-19, or other anti-sars-cov-2 biologic products within 6 months of screening has received any sars-cov-2 vaccine within 6 months prior to screening or is expected to receive a sars-cov-2 vaccine or other approved, authorized, or investigational postexposure prophylaxis treatments through day 38. participating in another interventional clinical study with an investigational compound or device, including those for covid-19 known or prior participation in this trial or another trial involving pf-07321332. females who are pregnant or breastfeeding.

history of sars-cov-2 infection in the past 6 months experiencing measured fever (documented temperature >38˚c or 100.4˚f) or other signs or symptoms consistent with covid-19 known medical history of active liver disease chronic kidney disease or have known moderate to severe renal impairment. known human immunodeficiency virus (hiv) infection with viral load > 400 copies/ml within the last 6 months or taking prohibited medications for hiv treatment suspected or confirmed concurrent active systemic infection active cancer requiring treatment with prohibited medication. current or expected use of any medications or substances that are highly dependent on cytochrome p450 3a4 (cyp3a4) for clearance or are strong inducers of cyp3a4 has received approved, authorized, or investigational anti-sars-cov-2 mab, convalescent plasma, other drugs for treatment of covid-19, or other anti-sars-cov-2 biologic products within 6 months of screening has received any sars-cov-2 vaccine within 6 months prior to screening or is expected to receive a sars-cov-2 vaccine or other approved, authorized, or investigational postexposure prophylaxis treatments through day 38. participating in another interventional clinical study with an investigational compound or device, including those for covid-19 known or prior participation in this trial or another trial involving pf-07321332. females who are pregnant or breastfeeding.

- history of sars-cov-2 infection - experiencing measured fever (documented temperature >38˚c or 100.4˚f) or other signs or symptoms consistent with covid-19 - known medical history of active liver disease - chronic kidney disease or have known moderate to severe renal impairment. - known human immunodeficiency virus (hiv) infection with viral load > 400 copies/ml within the last 6 months or taking prohibited medications for hiv treatment - suspected or confirmed concurrent active systemic infection - active cancer, other than localized skin cancer - current or expected use of any medications or substances that are highly dependent on cytochrome p450 3a4 (cyp3a4) for clearance or are strong inducers of cyp3a4 - has received approved, authorized, or investigational anti-sars-cov-2 mab, convalescent plasma, other drugs for treatment of covid-19, or other anti-sars-cov-2 biologic products - has received or is expected to receive a sars-cov-2 vaccine or other approved, authorized, or investigational postexposure prophylaxis treatments during the study period - participating in another interventional clinical study with an investigational compound or device, including those for covid-19 - known or prior participation in this trial or another trial involving pf-07321332. - females who are pregnant or breastfeeding.

- history of sars-cov-2 infection - experiencing measured fever (documented temperature >38˚c or 100.4˚f) or other signs or symptoms consistent with covid-19 - known medical history of active liver disease - chronic kidney disease or have known moderate to severe renal impairment. - known human immunodeficiency virus (hiv) infection with viral load > 400 copies/ml within the last 6 months or taking prohibited medications for hiv treatment - suspected or confirmed concurrent active systemic infection - active cancer, other than localized skin cancer - current or expected use of any medications or substances that are highly dependent on cytochrome p450 3a4 (cyp3a4) for clearance or are strong inducers of cyp3a4 - has received approved, authorized, or investigational anti-sars-cov-2 mab, convalescent plasma, other drugs for treatment of covid-19, or other anti-sars-cov-2 biologic products - has received or is expected to receive a sars-cov-2 vaccine or other approved, authorized, or investigational postexposure prophylaxis treatments during the study period - participating in another interventional clinical study with an investigational compound or device, including those for covid-19 - known or prior participation in this trial or another trial involving pf-07321332. - females who are pregnant or breastfeeding.